Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) DOYLESTOWN, Pa. , March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage
DOYLESTOWN, Pa. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has submitted an Investigational New Drug (IND)
DOYLESTOWN, Pa. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad , President and CEO, will deliver a
DOYLESTOWN, Pa. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update highlighting recent developments and
DOYLESTOWN, Pa. , Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics , Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET DOYLESTOWN, Pa. , Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on
DOYLESTOWN, Pa. , Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters presented at the AACR-NCI-EORTC
DOYLESTOWN, Pa. , Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023
Demonstrating potential safety and efficacy of WEE1 inhibitor, ATRN-1051, in the treatment of ovarian cancer Company anticipates submitting an IND by the end of 2023 Data to be presented at an upcoming 2023 scientific conference, with KOL event planned for the fall DOYLESTOWN, Pa. , Sept.
DOYLESTOWN, Pa. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad , Ph.D., President and Chief Executive
